000057851 001__ 57851
000057851 005__ 20161225203700.0
000057851 0247_ $$2pmid$$apmid:16309846
000057851 0247_ $$2DOI$$a10.1016/j.neuroscience.2005.10.005
000057851 0247_ $$2WOS$$aWOS:000235121000012
000057851 037__ $$aPreJuSER-57851
000057851 041__ $$aeng
000057851 082__ $$a610
000057851 084__ $$2WoS$$aNeurosciences
000057851 1001_ $$0P:(DE-HGF)0$$aGiessing, C.$$b0
000057851 245__ $$aThe modulatory effects of nicotine on parietal cortex activity in a cued target detection task depend on cue reliability
000057851 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2006
000057851 300__ $$a853 - 864
000057851 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000057851 3367_ $$2DataCite$$aOutput Types/Journal article
000057851 3367_ $$00$$2EndNote$$aJournal Article
000057851 3367_ $$2BibTeX$$aARTICLE
000057851 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000057851 3367_ $$2DRIVER$$aarticle
000057851 440_0 $$04579$$aNeuroscience$$v137$$x0306-4522$$y3
000057851 500__ $$aRecord converted from VDB: 12.11.2012
000057851 520__ $$aThis functional magnetic resonance imaging study investigates the effects of nicotine in a cued target detection task when changing cue reliability. Fifteen non-smoking volunteers were studied under placebo and nicotine (Nicorette polacrilex gum 1 and 2 mg). Validly and invalidly cued trials were arranged in blocks with high, middle and low cue reliability. Two effects of nicotine were investigated: its influence on i) parietal cortex activity underlying the processing of invalid vs. valid trials (i.e. validity effect) and ii) neural activity in the context of low, middle and high informative value of the cue (i.e. cue reliability effect). Nicotine did not affect behavioral performance. However, nicotine reduced the difference in the blood oxygenation level dependent (BOLD) signal between invalid and valid trials in the right intraparietal sulcus. The reduction of parietal activity in invalid trials was smaller in the low cue reliability condition. The same posterior parietal region exhibited a nicotinic modulation of BOLD activity in valid trials which was dependent on cue reliability: Nicotine specifically enhanced the neural activity during valid trials in the context of low cue reliability, i.e. when subjects are already in a state of low certainty. We speculate that the right intraparietal sulcus might be part of two networks working in parallel: one responsible for reorienting attention and the other for the cholinergic modulation of cue reliability. By reducing the use of the cue, nicotine modulates parietal activity related to reorienting attention in conditions with higher cue certainty. On the other hand, nicotine increases parietal activity in states of low certainty. This enhanced activation might influence brain regions, such as the posterior cingulate, directly involved in the processing of cue reliability.
000057851 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000057851 588__ $$aDataset connected to Web of Science, Pubmed
000057851 650_2 $$2MeSH$$aAdult
000057851 650_2 $$2MeSH$$aAttention: drug effects
000057851 650_2 $$2MeSH$$aCues
000057851 650_2 $$2MeSH$$aData Interpretation, Statistical
000057851 650_2 $$2MeSH$$aDose-Response Relationship, Drug
000057851 650_2 $$2MeSH$$aFemale
000057851 650_2 $$2MeSH$$aFunctional Laterality: physiology
000057851 650_2 $$2MeSH$$aHumans
000057851 650_2 $$2MeSH$$aImage Processing, Computer-Assisted
000057851 650_2 $$2MeSH$$aLearning: drug effects
000057851 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000057851 650_2 $$2MeSH$$aMale
000057851 650_2 $$2MeSH$$aNicotine: pharmacology
000057851 650_2 $$2MeSH$$aNicotinic Agonists: pharmacology
000057851 650_2 $$2MeSH$$aOxygen: blood
000057851 650_2 $$2MeSH$$aParietal Lobe: drug effects
000057851 650_2 $$2MeSH$$aPhotic Stimulation
000057851 650_2 $$2MeSH$$aPsychomotor Performance: drug effects
000057851 650_2 $$2MeSH$$aReaction Time: drug effects
000057851 650_7 $$00$$2NLM Chemicals$$aNicotinic Agonists
000057851 650_7 $$054-11-5$$2NLM Chemicals$$aNicotine
000057851 650_7 $$07782-44-7$$2NLM Chemicals$$aOxygen
000057851 650_7 $$2WoSType$$aJ
000057851 65320 $$2Author$$aacetylcholine
000057851 65320 $$2Author$$aattention
000057851 65320 $$2Author$$aPosner paradigm
000057851 65320 $$2Author$$atopdown
000057851 65320 $$2Author$$auncertainty
000057851 65320 $$2Author$$avalidity effect
000057851 7001_ $$0P:(DE-HGF)0$$aThiel, C. M.$$b1
000057851 7001_ $$0P:(DE-HGF)0$$aRösler, F.$$b2
000057851 7001_ $$0P:(DE-Juel1)131720$$aFink, G. R.$$b3$$uFZJ
000057851 773__ $$0PERI:(DE-600)1498423-4$$a10.1016/j.neuroscience.2005.10.005$$gVol. 137, p. 853 - 864$$p853 - 864$$q137<853 - 864$$tNeuroscience$$v137$$x0306-4522$$y2006
000057851 8567_ $$uhttp://dx.doi.org/10.1016/j.neuroscience.2005.10.005
000057851 909CO $$ooai:juser.fz-juelich.de:57851$$pVDB
000057851 9131_ $$0G:(DE-Juel1)FUEK409$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000057851 9141_ $$aNachtrag$$y2006
000057851 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000057851 9201_ $$0I:(DE-Juel1)VDB54$$d31.12.2006$$gIME$$kIME$$lInstitut für Medizin$$x1
000057851 970__ $$aVDB:(DE-Juel1)90984
000057851 980__ $$aVDB
000057851 980__ $$aConvertedRecord
000057851 980__ $$ajournal
000057851 980__ $$aI:(DE-Juel1)INB-3-20090406
000057851 980__ $$aUNRESTRICTED
000057851 981__ $$aI:(DE-Juel1)INB-3-20090406